Navigation Links
PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting
Date:12/6/2007

alysis of real-world data from ESA-treated oncology

patients obtained from an ongoing prospective, observational registry,

Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies

(DOSE), to characterize hemoglobin levels or transfusion triggers.

Data were collected from participating hospital- and community-based

outpatient practices between December 2003 and July 2007.

About PROCRIT (Epoetin alfa)

PROCRIT is used for the treatment of anemia in patients with most types of cancer receiving chemotherapy, with chronic renal failure who are on dialysis and those who are not on dialysis, who are being treated with zidovudine for HIV infection, and to reduce the need for transfusion in anemic patients who are scheduled for elective noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ.

Important U.S. Safety Information for PROCRIT

Boxed WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR AND THROMBOEMBOLIC EVENTS, and TUMOR PROGRESSION

Renal failure: Patients experienced greater risks for death and serious cardiovascular events when administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

-- ESAs shortened overall survival and/or time-to-tumor progression in

clinical studies in patients with advanced breast, head and neck,

lymphoid, and non-small cell lung malignancies when dosed to target a

hemoglobin of greater than or equal to 12 g/dL.

-- The risks of shortened survival and tumor progression have not been

excluded when ESAs are dosed to target a hemoglobin of < 12 g/dL.

-- To minimize these risks, as well as the risk of serious cardio- a
'/>"/>

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... , Aug. 19, 2014  As power morcellator ... country, Bernstein Liebhard LLP notes that women in ... between a number of options that do not ... instrument. According to a report published by The ... these options include a mini-laparotomy and vaginal hysterectomy. ...
(Date:8/19/2014)... RIDGEFIELD, Conn. , Aug. 19, 2014 /PRNewswire/ ... and Drug Administration (FDA) accepted for review the ... (FDC) of tiotropium and olodaterol delivered via the ... of long-term, once-daily maintenance treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. Tiotropium + olodaterol ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Cardiovascular Devices: Technologies ... , Offer a comprehensive view of the cardiovascular devices ... of the major types of cardiovascular diagnostic equipment, including ...
... , ... new market research report is available in its catalogue: ... Trends , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The ... a flurry of activity with pharmaceutical companies adding chiral ...
Cached Medicine Technology:Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 2Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 3Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 4Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 5Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 6Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 7Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 8Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 9Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 10Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 11Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 12Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5
(Date:8/20/2014)... 20, 2014 “Have you recently been involved ... and personal injury lawyer serving the greater Seattle area. “Are ... so, then keep reading . , In a recently ... in an auto accident can use to see if they ... a personal injury insurance claim will allow an individual to ...
(Date:8/20/2014)... The “Human Insulin Market by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2019” provides a detailed ... market trends,and strategies impacting the global human insulin ... the revenue and share analysis. , Browse 110 ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... August 20, 2014 Over 31 million Americans ... of Disease, low back pain is the single leading cause ... reasons for missed work. Americans spend at least $50 billion ... Most cases of back pain are not due to organic ... , For example, Pete, a busy accountant, had little time ...
(Date:8/19/2014)... in Houston, Texas, is pleased to announce it is now ... with old fillings that need replacing, will benefit from the ... teeth. , From now on any cavities will be repaired ... amalgam free. Even though amalgam fillings have been deemed as ... children over the age of six, they do contain mercury ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... New Rochelle, NY, August 6, 2009The more time college ... to feel jealous toward their romantic partners, leading to ... will further fuel their jealousy, in an escalating cycle ... in CyberPsychology & Behavior , a peer-reviewed journal ...
... Gene signature detects differences in viral, bacterial infections, ... -- A genomic "signature" in blood appears able to ... viruses, such as the cold or flu, even before ... volunteers who were infected with either a live cold ...
... , , , ... Board: PSTX) today announced record quarterly revenues. , , ... Steven H. Kane, Chief Executive Officer of Patient Safety Technologies. ... adopting the Safety Sponge((TM)) System as the solution to the problem ...
... SOUTH PASADENA, Calif., Aug. 6 California Cancer ... center in South Pasadena. The 22,000 s.f. facility, operating under ... in medical, surgical and radiation oncology. In addition, ... San Gabriel Valley to offer RapidArc((TM)), a new and highly ...
... STAMFORD, Conn., Aug. 6 The Purdue Products L.P. ... the National Association of Chain Drug Stores (NACDS) 2009 Marketplace Conference, ... and the primary ingredient is the deseeded pod of the senna ... ) , , "We,ve always ...
... , Report Shows That Making Americans ... , , SAN DIEGO, Aug. 6 As ... decline in public support for health reform efforts, new research shows ... moving the reform needle. , , The ...
Cached Medicine News:Health News:Does Facebook usage contribute to jealousy in relationships? 2Health News:Cold, Flu or Pneumonia? Answer May Lie in Blood Test 2Health News:Patient Safety Technologies Reports Second Quarter Results 2Health News:Patient Safety Technologies Reports Second Quarter Results 3Health News:Patient Safety Technologies Reports Second Quarter Results 4Health News:Patient Safety Technologies Reports Second Quarter Results 5Health News:Patient Safety Technologies Reports Second Quarter Results 6Health News:Patient Safety Technologies Reports Second Quarter Results 7Health News:California Cancer Specialists Medical Group, Inc. Opens Outpatient Cancer Center in South Pasadena, Calif., With Renowned Medical Staff, State-of-the-Art Technology 2Health News:Senokot(R) Tablets Undergo a Natural Makeover 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 3Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 4Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 5Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 6
... provides the most useful measurement for ... states. It is the preferred diagnostic ... patients who have experienced changes in ... dehydration. It is also used to ...
... HemoCue Hemoglobin Test Systems ... reliable quantitative hemoglobin results ... as a large hematology ... consists of either the ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: